All In MedTech

Device Trial Radar · NCT02748408

The Medacta International SMS Post-Marketing Surveillance Study

The Medacta SMS Femoral Stem Component. A Multi-National, Multi-Centre, Clinical Surveillance Study

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Jul 2015

Primary completion

Jul 2032

Study completion Jul 2032

Sponsor

Lead sponsor
Medacta International SANot on our public-company list
Sponsor type
Industry
First posted
Apr 22, 2016

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.

Conditions

  • Arthrosis
  • Traumatic Arthritis
  • Rheumatoid Polyarthritis
  • Congenital Hip Dysplasia
  • Avascular Necrosis of the Femoral Head

Interventions

  • SMS femoral stemDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survivorship of the Medacta SMS femoral stemTime frame: 10-year

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Herz-Jesu Krankenhaus

    Vienna, Austria · Recruiting

  • Istituto Ortopedico Galezzi

    Milan, Milan, Italy · Recruiting

  • Bürgerspital Solothurn

    Solothurn, Switzerland · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.